Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
50%(4 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
3
27%
Ph phase_2
2
18%
Ph phase_3
3
27%

Phase Distribution

3

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(2)
Other(1)

Detailed Status

Completed8
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 22 (25.0%)
Phase 33 (37.5%)

Trials by Status

unknown19%
completed873%
terminated218%

Recent Activity

0 active trials
Showing 5 of 11
unknown

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

NCT01798914
completed

A 2-Month Safety Follow-Up Trial

NCT00741429
terminatedphase_3

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

NCT01196104
completedphase_3

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
completedphase_2

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01798914

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Unknown
NCT00741429

A 2-Month Safety Follow-Up Trial

Completed
NCT01196104Phase 3

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Terminated
NCT00309244Phase 3

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Completed
NCT00662857Phase 2

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Completed
NCT00308737Phase 3

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

Completed
NCT01544881Phase 1

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Completed
NCT01201928

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

Terminated
NCT01365117Phase 1

Pharmacokinetic Study in Healthy Volunteers

Completed
NCT00673621Phase 1

A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics

Completed
NCT00934414Phase 2

Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11